Isolation of native human monoclonal autoantibodies to breast cancer
Isolation of native human monoclonal autoantibodies to breast cancer
复制标题
DOI：
10.1089/153685902321043936
复制
发表时间：
2002-12-01
期刊：
影响因子：
--
通讯作者：
Trakht, I
中科院分区：
文献类型：
--
作者：
Kirman, I;Kalantarov, GF;Trakht, I
利用一种独特的融合伙伴细胞系MFP-2和乳腺癌患者的B淋巴细胞，我们开发了一组与乳腺癌细胞具有高特异性和敏感性的全人单抗(MAb)。对正常组织、原发肿瘤和转移淋巴结的免疫荧光染色表明，这些抗体对自体和异体起源的乳腺癌是特异的。我们还确定，许多基于与乳腺癌细胞和组织的特异性结合而选择的抗体也以高度的特异性和敏感性结合前列腺癌细胞和组织。这些抗体的靶点已经定位在细胞质和细胞膜上。内化和细胞毒性的生物学检测表明，三种抗体具有快速内化的能力。我们的研究表明，从天然抗体库中分离针对癌细胞的天然人单抗是可行的，并可能为免疫治疗提供工具来源。
Using a unique fusion partner cell line, MFP-2, and B-lymphocytes from breast cancer patients, we developed a set of fully human monoclonal antibodies (MAbs) that bind with high specificity and sensitivity to breast cancer cells. Immunofluorescent staining of normal tissues, primary tumors, and metastatic lymph nodes demonstrates that these antibodies are specific for breast cancer of autologous; and allogeneic origin. We have also determined that many of the antibodies selected based on specific binding to breast cancer cells and tissue also bind prostate cancer cells and tissue with high specificity and sensitivity. The targets of these antibodies have been localized to the cytoplasm and membrane. Biological assays for internalization and cytotoxicity demonstrated the ability of three antibodies to rapidly internalize. Our study demonstrates that isolation of native human MAbs from the natural antibody repertoire, targeted to cancer cells, is feasible and may provide a source of tools for immunotherapy.